[1]李 辉,安盟盟,张 会,等.司美格鲁肽联合非诺贝特治疗2型糖尿病合并非酒精性脂肪性肝病疗效及安全性观察[J].陕西医学杂志,2025,54(3):378-383.[doi:DOI:10.3969/j.issn.1000-7377.2025.03.018]
　LI Hui,AN Mengmeng,ZHANG Hui,et al.Efficacy and safety of semaglutide combined with fenofibrate in treatment of T2DM complicated with NAFLD[J].,2025,54(3):378-383.[doi:DOI:10.3969/j.issn.1000-7377.2025.03.018]
点击复制

司美格鲁肽联合非诺贝特治疗2型糖尿病合并非酒精性脂肪性肝病疗效及安全性观察
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
54
期数:
2025年3期
页码:
378-383
栏目:
药物与临床
出版日期:
2025-03-05

文章信息/Info

Title:
Efficacy and safety of semaglutide combined with fenofibrate in treatment of T2DM complicated with NAFLD
作者:
李 辉1; 安盟盟1; 张 会2; 刘建凤1; 张 于1; 袁 敏1; 刘金良3
(1.沧州市人民医院肿瘤院区内分泌代谢科,河北 沧州 061000; 2.沧州市人民医院肿瘤院区血液内科,河北 沧州 061000; 3.沧州市人民医院肿瘤院区医学影像科,河北 沧州 061000)
Author(s):
LI Hui1; AN Mengmeng1; ZHANG Hui2; LIU Jianfeng1; ZHANG Yu1; YUAN Min1; LIU Jinliang3
(1.Department of Endocrinology and Metabolism,Cancer Campus,Cangzhou People's Hospital,Cangzhou 061000,China; 2.Department of Hematology,Cancer Campus,Cangzhou People's Hospital,Cangzhou 061000,China; 3.Department of Medical Imaging,Cancer Campus,Cangzhou People's Hospital,Cangzhou 061000,China)
关键词:
2型糖尿病;  非酒精性脂肪性肝病;  司美格鲁肽;  非诺贝特;  肝纤维化;  肝功能
Keywords:
Type 2 diabetes mellitus;  Non-alcoholic fatty liver disease;  Semaglutide;  Fenofibrate;  Liver fibrosis;  Liver function
分类号:
R 587.1
DOI:
DOI:10.3969/j.issn.1000-7377.2025.03.018
文献标志码:
A
摘要:
目的:探究司美格鲁肽联合非诺贝特治疗2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)的疗效及安全性。方法:将97例T2DM合并NAFLD患者随机分为观察组(47例)和对照组(50例),对照组采用常规治疗联合非诺贝特胶囊治疗,观察组在对照组基础上给予司美格鲁肽治疗。比较两组疗效、体重指数(BMI)、体重、肝/脾CT值、胰岛素相关指标、糖脂代谢指标、肝功能指标、血管内皮功能指标、氧化应激指标、血清肝纤维化指标以及不良反应发生率。结果:观察组临床疗效高于对照组(P<0.05)。治疗后,与对照组比较,观察组BMI、体重、胰岛素抵抗指数(HOMA-IR)、肝脏脂肪含量(LFC)、胰岛素敏感指数(HOMA-ISI)、丙二醛(MDA)、8-异前列腺素F2α(8-iso-PGF2α)、透明质酸(HA)、层粘连蛋白(LN)、Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(CⅣ)、空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)、三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、丙氨酸氨基转氨酶(ALT)、天冬氨酸氨基转移酶(AST)、谷氨酰胺转移酶(GGT)、血清内皮素(ET)、血栓素B2(TXB2)水平下降,前列环素(PGI2)、一氧化氮(NO)、肝/脾CT值、谷胱甘肽过氧化物酶(GSH-Px)水平升高(均P<0.05)。两组不良反应总发生率比较差异无统计学意义(P>0.05)。结论:司美格鲁肽联合非诺贝特能改善T2DM合并NAFLD患者糖脂代谢、肝功能、内皮功能、肝纤维化及氧化应激水平,具有良好的安全性。
Abstract:
Objective:To investigate the efficacy and safety of semaglutide combined with fenofibrate in the treatment of T2DM complicated with NAFLD.Methods:A total of 97 T2DM patients complicated with NAFLD were randomly divided into observation group(47 cases)and control group(50 cases).The control group was treated with conventional treatment combined with fenofibrate capsule,and the observation group was treated with semaglutide on basis of control group.The efficacy,BMI,body weight,liver/spleen CT value,insulin-related indicators,glucose and lipid metabolism indicators,liver function indicators,vascular endothelial function indicators,oxidative stress indicators,serum liver fibrosis indicators,and the incidence of adverse reactions were compared between two groups.Results:The efficacy of observation group was higher than that of control group(P<0.05).After treatment,compared with the control group,the BMI,body weight,HOMA-IR,LFC,HOMA-ISI,MDA,8-iso-PGF2α,HA,LN,PCⅢ,CⅣ,FPG,2hPG,HbA1c,TG,TC,LDL-C,ALT,AST,GGT,ET,TXB2,PGI2,NO,liver/spleen CT value and GSH-Px were increased(all P<0.05).There was no significant difference in the total incidence of adverse reactions between two groups(P>0.05).Conclusion:Semaglutide combined with fenofibrate can improve glucose and lipid metabolism,liver function,endothelial function,liver fibrosis and oxidative stress level in T2DM patients complicated with NAFLD,with good safety.

参考文献/References:

[1] FURTHNER D,WEGHUBER D,DALUS C,et al.Nonalcoholic fatty liver disease in children with obesity:Narrative review and research gaps[J].Horm Res Paediatr,2022,95(2):167-176.
[2] 李真真,白杨,黄婷.非诺贝特联合胰岛素治疗2型糖尿病合并非酒精性脂肪肝病患者疗效观察[J].肝脏,2022,27(1):103-122.
[3] REN H,ZHAO L,ZOU Y,et al.Association between atherosclerotic cardiovascular diseases risk and renal outcome in patients with type 2 diabetes mellitus[J].Ren Fail,2021,43(1):477-487.
[4] 李晓峰,施羽,卫东琴.司美格鲁肽治疗胰岛素抗体阳性2型糖尿病1例[J].中华糖尿病杂志,2022,14(Z1):200-203.
[5] 朱豆豆,朱升龙,崔思远,等.胆固醇酯对非酒精性脂肪肝药物治疗的影响[J].食品与生物技术学报,2023,42(7):11-17.
[6] 李畅,史琳涛,李广琦,等.WHO与IADPSG诊断标准关于妊娠期糖尿病诊断率的对比[J].中国糖尿病杂志,2014,22(5):385-388.
[7] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪肝病诊疗指南[J].胃肠病学,2010,15(11):676-680.
[8] 闫炜,郭丹,孙晓婷.T2DM合并NAFLD患者血清小而密低密度脂蛋白变化及与胰岛素抵抗脂肪衰减指数的关系分析[J].河北医学,2023,29(11):1868-1872.
[9] 沈伟,胡军平,黄昌秀.滋阴降糖方治疗2型糖尿病疗效及对患者血糖波动相关指标、胰岛功能的影响[J].陕西中医,2024,45(9):1199-1202.
[10] BRUNS B,JOOS M,ELSOUS N,et al.Insulin resistance in Takotsubo syndrome[J].ESC Heart Fai,2024,11(3):1515-1524.
[11] 邹耀武.菖蒲郁金汤加减对T2DM合并NAFLD患者糖脂代谢异常及胰岛素抵抗的影响[J].现代中西医结合杂志,2022,31(3):389-392.
[12] JIANG S,UDDIN M J,YU X,et al.Peroxisomal fitness:A potential protective mechanism of fenofibrate against high fat diet-induced non-alcoholic fatty liver disease in mice[J].Diabetes Metab J,2022,46(6):829-842.
[13] 郑丽华,巴?巴音斯勒玛,王思瑶,等.非诺贝特联合替格瑞洛对冠心病合并高三酰甘油血症患者脂代谢及凝血功能的影响[J].实用心脑肺血管病杂志,2024,32(6):98-102.
[14] 韩美芬,赵彬,陈伟,等.司美格鲁肽在治疗肥胖症中的作用机制及临床应用进展[J].中国新药杂志,2022,31(9):859-862.
[15] 乐颖,薛萌.司美格鲁肽治疗肢端肥大症致继发性糖尿病1例[J].中华糖尿病杂志,2022,14(1):141-143.
[16] 李振兴,白秋江.司美格鲁肽临床和安全性的研究进展[J].药物评价研究,2024,47(3):657-664.
[17] 孟祥雨,白立炜,尹清风,等.司美格鲁肽治疗2型糖尿病合并非酒精性脂肪肝病的临床疗效及对氧化应激和炎症因子的影响[J].新乡医学院学报,2024,41(5):443-448.
[18] YU C,GUO X,CUI X,et al.Functional food chemical ingredient strategies for non-alcoholic fatty liver disease(NAFLD)and hepatic fibrosis:Chemical properties,health benefits,action,and application[J].Curr Nutr Rep,2024,13(1):1-14.
[19] 赵梦溪,罗斌,吕建瑞,等.隐丹参酮治疗小鼠非酒精性脂肪性肝病效果及机制研究[J].陕西医学杂志,2023,52(9):1135-1144.
[20] 赵立昌,袁超,殷娜,等.参麦地黄汤联合缬沙坦对糖尿病肾病患者氧化应激、血管内皮功能及血清miR-133b、miR-135b的影响[J].南京中医药大学学报,2023,39(10):1034-1038.
[21] JIN L,HUA H,JI Y,et al.Anti-inflammatory role of fenofibrate in treating diseases[J].Biomol Biomed,2023,23(3):376-391.
[22] GUPTA V,GARG A,TOMAR R,et al.Oxidative stress:Meeting multiple targets in pathogenesis of vascular endothelial dysfunction[J].Curr Drug Targets,2022,23(9):902-912.
[23] 谢婧,徐斌,赵铎,等.司美格鲁肽在首次或既往使用胰高血糖素样肽-1受体激动剂的2型糖尿病患者中有效性的系统评价[J].临床药物治疗杂志,2023,21(8):33-40.
[24] 仝俊瑶,倪银星.司美格鲁肽联合门冬胰岛素30治疗老年2型糖尿病患者的临床研究[J].中国临床药理学杂志,2023,39(23):3370-3374.
[25] 高泽林,杨淑彬.艾塞那肽与沙格列汀分别联合二甲双胍治疗腹型肥胖2型糖尿病疗效及安全性对比研究[J].陕西医学杂志,2024,53(9):1240-1244.

相似文献/References:

[1]李艳艳,贾 伟△.24h动态心电图在2型糖尿病合并冠心病患者心律诊断中的价值分析[J].陕西医学杂志,2019,(1):61.
[2]郭向东,马 波△.2型糖尿病患者血清胰岛素水平与骨代谢关联研究*[J].陕西医学杂志,2019,(1):77.
　GUO Xiangdong,MA Bo..Association between serum insulin level and bone metabolismin patients with type 2 diabetes mellitus[J].,2019,(3):77.
[3]刘毅龙,陈鹏宇,雷 江,等.SGLT2抑制剂在2型糖尿病合并心血管疾病治疗中的应用研究进展[J].陕西医学杂志,2019,(3):407.
[4]姚爱红.利拉鲁肽治疗2型糖尿病效果及对患者血脂、颈动脉内膜中层厚度的影响[J].陕西医学杂志,2019,(4):518.
　YAO Aihong..Effect of liraglutide on type 2 diabetes mellitus in patients with blood lipids and carotid intimamedia thickness[J].,2019,(3):518.
[5]李忆琴,吴礼凤,余晓君,等.中年2型糖尿病患者病程和HbA1c水平与认知功能相关性研究*[J].陕西医学杂志,2019,(6):722.
[6]徐 琳,贾睿博△,宋民喜,等.颗粒蛋白前体与糖尿病肾病关系探讨*[J].陕西医学杂志,2019,(8):1024.
[7]王荣锋,郁 昊,蒋新建.老年糖尿病患者血清25羟维生素D水平与骨质疏松相关性研究[J].陕西医学杂志,2019,(8):1032.
　WANG Rongfeng,YU Hao,JIANG Xinjian..The relationship between serum 25 hydroxy vitamin D and osteoporosis in elderly diabetic patients[J].,2019,(3):1032.
[8]王 荣,贾爱华,刘新艳 ,等.IGF1及其相关性因素对2型糖尿病并发骨质疏松的影响研究[J].陕西医学杂志,2019,(9):1163.
　WANG Rong,JIA Aihua,LIU Xinyan,et al.The effect of IGF1 and its related factors in type 2 diabetes complicated with osteoporosis[J].,2019,(3):1163.
[9]贾睿博,徐 琳△.2型糖尿病患者下肢血管病变相关危险因素调查研究[J].陕西医学杂志,2019,(11):1567.
[10]郭建强,赵俊宏,张分队,等.2型糖尿病视网膜病变患者血清HbA1c、CysC检测及临床意义*[J].陕西医学杂志,2020,49(5):619.
　GUO Jianqiang,ZHAO Junhong,ZHANG Fendui,et al.Changes of serum HbA1c and CysC in patients with type 2 diabetic retinopathy and their clinical significance[J].,2020,49(3):619.
[11]安 欣,刘鲁豫,王成凯.2型糖尿病患者尿微量白蛋白肌酐比值与非酒精性脂肪性肝病相关性分析[J].陕西医学杂志,2021,50(11):1416.[doi:DOI:10.3969/j.issn.1000-7377.2021.11.023]
[12]高佳敏,王 涛,朱云峰,等.尿酸/高密度脂蛋白胆固醇比值对2型糖尿病合并非酒精性脂肪性肝病的预测价值[J].陕西医学杂志,2025,54(3):323.[doi:DOI:10.3969/j.issn.1000-7377.2025.03.007]
　GAO Jiamin,WANG Tao,ZHU Yunfeng,et al.Value of UHR in predicting type 2 diabetes mellitus combined with NAFLD[J].,2025,54(3):323.[doi:DOI:10.3969/j.issn.1000-7377.2025.03.007]

备注/Memo

备注/Memo:
[基金项目]河北省医学科学研究课题(20200296)
更新日期/Last Update: 2025-03-05